Advertisement

Gastric Cancer

, Volume 22, Issue 4, pp 778–784 | Cite as

Association between UGT1A1 gene polymorphism and safety and efficacy of irinotecan monotherapy as the third-line treatment for advanced gastric cancer

  • Toshifumi YamaguchiEmail author
  • Satoru Iwasa
  • Hirokazu Shoji
  • Yoshitaka Honma
  • Atsuo Takashima
  • Ken Kato
  • Tetsuya Hamaguchi
  • Kazuhide Higuchi
  • Narikazu Boku
Original Article
  • 378 Downloads

Abstract

Background

While uridine diphosphate glucuronosyltransferase (UGT) 1A1 is a key enzyme in the metabolism of irinotecan, relationship between UGT1A1 genotype and safety and efficacy of irinotecan monotherapy in patients with advanced gastric cancer is not clarified.

Methods

Efficacy and safety in advanced gastric cancer patients, who were tested for UGT1A1*6 and *28 genotype and treated with irinotecan monotherapy as third-line treatment from 2009 to 2014, were evaluated according to the UGT1A1*6 and *28 genotypes.

Results

Among 74 patients of the subjects, the genotypes of UGT1A1 were wild-type (WT) in 37 patients (50%), single heterozygosity (SH) in 27 (36.5%) and double heterozygosity or homozygosity (Homo/DH) in 10 (13.5%). The initial dose of irinotecan was reduced in 10 patients (27%) with WT, in 9 (33%) with SH, and in 7 (70%) with Homo/DH. Median overall survival was 6.9 months, 6.3 months, and 2.8 months in the WT, SH and Homo/DH genotypes, associated with median time to treatment failure of 2.4 months, 2.3 months, and 1.3 months, respectively. Among 36 patients with measurable lesion, disease control rates were 47.6%, 41.7% and 33.3% in the WT, SH and Homo/DH genotypes. Grade 3 or higher adverse events of special interest were neutropenia (13%, 22%, and 64% for the WT, SH and Homo/DH genotypes), febrile neutropenia (2%, 7%, and 50%) and diarrhea (6%, 5%, and 21%).

Conclusions

The UGT1A1 polymorphism may be related to the clinical outcomes of irinotecan monotherapy as the third-line treatment for advanced gastric cancer.

Keywords

Gastric cancer UGT1A1 Irinotecan 

Notes

Compliance with ethical standards

Conflict of interest

None of the authors have conflicts of interest to declare.

Research involving human participants

All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964 and later versions. Informed consent or substitute for it was obtained from all patients for being included in the study.

References

  1. 1.
    Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, et al. Randomized phase III study of S-1 alone versus S-1+ cisplatin in the treatment for advanced gastric cancer (The SPIRITS trial) SPIRITS:S-1 plus cisplatin vs S-1 in RCT in the treatment for stomach cancer. Lancet Oncol. 2008;9:215–21.CrossRefGoogle Scholar
  2. 2.
    Boku N, Yamamoto S, Shirao K, Doi T, Sawaki A, Koizumi W, et al. Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer:a randomized phase3 study. Lancet Oncol. 2009;10:1063–9.CrossRefGoogle Scholar
  3. 3.
    Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA):a phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687–97.CrossRefGoogle Scholar
  4. 4.
    Thuss-Patience PC, Kretzschmar A, Bichev D, Deist T, Hinke A, Breithaupt K, et al. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer—a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Eur J Cancer. 2011 Oct;47(15):2306–14.CrossRefGoogle Scholar
  5. 5.
    Ford HE, Marshall A, Bridgewater JA, Janowitz T, Coxon FY, Wadsley J, et al. Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial. Lancet Oncol. 2014 15(1):78–86.CrossRefGoogle Scholar
  6. 6.
    Kang JH, Lee SI, Lim DH, Park KW, Oh SY, Kwon HC, et al. Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. J Clin Oncol. 2012 30(13):1513–8.CrossRefGoogle Scholar
  7. 7.
    Hironaka S, Ueda S, Yasui H, Nishina T, Tsuda M, Tsumura T, et al. Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial. J Clin Oncol. 2013 31(35):4438–44.CrossRefGoogle Scholar
  8. 8.
    Wilke H, Muro K, Van Cutsem E, Oh SC, Bodoky G, Shimada Y, et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol. 2014;15(11):1224–35.CrossRefGoogle Scholar
  9. 9.
    Kang YK, Boku N, Satoh T, Ryu MH, Chao Y, Kato K, et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017 390(10111):2461–71.CrossRefGoogle Scholar
  10. 10.
    Fujita K, Sparreboom A. Pharmacogenetics of irinotecan disposition and toxicity: a review. Curr Clin Pharmacol. 2010 5(3):209–17.CrossRefGoogle Scholar
  11. 11.
    O’Dwyer PJ, Catalano RB. Uridine diphosphate glucuronosyltransferase (UGT) 1A1 and irinotecan: practical pharmacogenomics arrives in cancer therapy. J Clin Oncol. 2006 24(28):4534–8.CrossRefGoogle Scholar
  12. 12.
    Fujita K, Ando Y, Nagashima F, Yamamoto W, Yamamoto W, Eodo H, Araki K, et al. Genetic linkage of UGT1A7 and UGT1A9 polymorphisms to UGT1A1*6 is associated with reduced activity for SN-38 in Japanese patients with cancer. Cancer Chemother Pharmacol. 2007;60:515–22.CrossRefGoogle Scholar
  13. 13.
    Ando Y, Saka H, Ando M, Sawa T, Muro K, Ueoka H, et al. Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res. 2000 60(24):6921–6.Google Scholar
  14. 14.
    Innocenti F, Undevia SD, Iyer L, Chen PX, Das S, Kocherginsky M, et al. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol. 2004 22(8):1382–8.CrossRefGoogle Scholar
  15. 15.
    D’Andrea M, Pasetto LM, Pessa S, Russo A, Buonadonna A, D’Andrea M, et al. The role of UGT1A1*28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer. J Clin Oncol. 2006;24:3061–8.CrossRefGoogle Scholar
  16. 16.
    Kurose K, Sugiyama E, Saito Y. Population differences in major functional polymorphisms of pharmacokinetics/pharmacodynamics-related genes in Eastern Asians and Europeans: implications in the clinical trials for novel drug development. Drug Metab Pharmacokinet. 2012;27(1):9–54.CrossRefGoogle Scholar
  17. 17.
    Onoue M, Terada T, Kobayashi M, Katsura T, Matsumoto S, Yanagihara K, et al. UGT1A1*6 polymorphism is most predictive of severe neutropenia induced by irinotecan in Japanese cancer patients. Int J Clin Oncol. 2009 14(2):136–42.CrossRefGoogle Scholar
  18. 18.
    Xu C, Tang X, Qu Y, Keyoumu S, Zhou N, Tang Y.et al. UGT1A1 gene polymorphism is associated with toxicity and clinical efficacy of irinotecan-based chemotherapy in patients with advanced colorectal cancer. Cancer Chemother Pharmacol. 2016 78(1):119–30.CrossRefGoogle Scholar
  19. 19.
    Ichikawa W, Uehara K, Minamimura K, Tanaka C, Takii Y, Miyauchi H, et al. An internally and externally validated nomogram for predicting the risk of irinotecan-induced severe neutropenia in advanced colorectal cancer patients. Br J Cancer. 2015 112(10):1709–16.CrossRefGoogle Scholar
  20. 20.
    Makiyama A, Arimizu K, Hirano G, Makiyama C, Matsushita Y, Shirakawa T, et al. Irinotecan monotherapy as third-line or later treatment in advanced gastric cancer. Gastric Cancer. 2018 21(3):464–72.CrossRefGoogle Scholar
  21. 21.
    Kawakami T, Machida N, Yasui H, Kawahira M, Kawai S, Kito Y, et al. Efficacy and safety of irinotecan monotherapy as third-line treatment for advanced gastric cancer. Cancer Chemother Pharmacol. 2016 78(4):809–14.CrossRefGoogle Scholar
  22. 22.
    Nishimura T, Iwasa S, Nagashima K, Okita N, Takashima A, Honma Y, et al. Irinotecan monotherapy as third-line treatment for advanced gastric cancer refractory to fluoropyrimidines, platinum, and taxanes. Gastric Cancer. 2017 20(4):655–62.CrossRefGoogle Scholar
  23. 23.
    Ohtsu A, Ajani JA, Bai YX, Bang YJ, Chung HC, Pan HM, et al. Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE-1 study. J Clin Oncol. 2013 31(31):3935–43.CrossRefGoogle Scholar

Copyright information

© The International Gastric Cancer Association and The Japanese Gastric Cancer Association 2019

Authors and Affiliations

  1. 1.Cancer Chemotherapy CenterOsaka Medical College HospitalTakatsukiJapan
  2. 2.Second Department of Internal MedicineOsaka Medical CollegeTakatsukiJapan
  3. 3.Gastrointestinal Oncology DivisionNational Cancer Center HospitalTokyoJapan
  4. 4.Department of Gastrointestinal OncologySaitama Medical University International Medical CenterHidakaJapan

Personalised recommendations